CTXR
Citius Pharmaceuticals, Inc.
Key Financials
Net Income
$-32542912
↑ 3.3%
Gross Profit
$4.5M
N/A
Operating Income
$-38525608
↑ 8.3%
Revenue
$0
NaN%
EPS (Diluted)
$-3.38
↑ 43.4%
Cash & Equivalents
$4.3M
↑ 30.8%
Total Liabilities
$53.4M
↑ 25.5%
Shareholders' Equity
$67.6M
↓ 3.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13D/A | 6/4/2026 | View on SEC |
| EFFECT | 6/2/2026 | View on SEC |
| 8-K | 6/1/2026 | View on SEC |
| S-3 | 5/22/2026 | View on SEC |
| 8-K | 5/15/2026 | View on SEC |
| 10-Q | 5/15/2026 | View on SEC |
| 8-K | 5/8/2026 | View on SEC |
| 8-K | 4/29/2026 | View on SEC |
| 8-K | 4/24/2026 | View on SEC |
| 424B5 | 4/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CTXR |
| Company Name | Citius Pharmaceuticals, Inc. |
| CIK | 1506251 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0930 |
| State of Incorporation | NV |
| Phone | (908) 967-6676 |